David Fischer holds a degree in Chemistry and a PhD in Molecular Genetics, from Leiden University in The Netherlands. After six years of post-doctoral fellowships at the Netherlands Institute for Neuroscience in Amsterdam and the Free University Amsterdam he joined Galapagos. Charles River acquired the service operations from Galapagos in 2014.
As Chief Technology Officer focusing on early discovery, David works across the Charles River business units to help expedite our clients’ drug discovery and development programs. Furthermore, he works with our strategic partners to bring in cutting edge drug discovery platforms and technologies. In addition, David collaborates with Charles River colleagues in pharmacology, safety assessment, and CDMO on personalized (“n=1”) drug therapies, often for single patients with an ultra-rare disease.